Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study.
We hypothesized that heightened systemic inflammation contributes to the increased rate of cardiovascular events in HIV-infected patients not receiving combination antiretroviral therapy. We performed a pilot trial to assess the effects of the nuclear factor-kappaB inhibitor salsalate on flow-mediated dilation of the brachial artery, a measure of endothelial function. Flow-mediated dilation significantly improved after 8 weeks of salsalate. However, hepatotoxicity occurred frequently. Research using alternative agents is warranted to examine the role of inflammation in HIV-related cardiovascular disease.
Gupta
Samir K
SK
Indiana University School of Medicine, Indianapolis, Indiana, USA.
Johnson
Raymond M
RM
Saha
Chandan
C
Mather
Kieren J
KJ
Greenwald
Martha L
ML
Waltz
Jeffrey S
JS
Rehman
Jalees
J
Dubé
Michael P
MP
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001916:Brachial Artery / Q000502:physiology; D002318:Cardiovascular Diseases / Q000503:physiopathology / Q000821:virology*; D004730:Endothelium, Vascular / Q000503:physiopathology*; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D010865:Pilot Projects; D012459:Salicylates / Q000009:adverse effects / Q000627:therapeutic use*; D014664:Vasodilation / Q000187:drug effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016328:NF-kappa B; D012459:Salicylates; C014182:salicylsalicylic acid